Update COVID-19

In compliance with all the local and national guidelines and decrees on the COVID-19 emergency,
Axxam has implemented strict contingency measures in order to protect
the safety of the employees while preserving lab-based work and business continuity.

Even in these times of uncertainty, the Axxam Team is here to fully support
our Clients and Partners with the usual energy, strength and passion.

The Axxam Team would like to applaud to the medical community, in Italy and around the globe,
for their courage and commitment in their restless fight for save the life of patients.

Axxam is an innovative Partner Research Organization (iPRO). We are a leading provider of integrated discovery services across Life Sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural)  or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.

Discovery Services

Cell-based Assay

Development

Biochemical Assay

Development

High-Throughput

Screening

Hit Follow-up and

Electrophysiology

Compound Collections

Ready-to-go Assays

Live the i-PRO experience

Selonterra and Axxam Enter into Drug Discovery Collaboration

Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy - Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading...

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with...

Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2

Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2 Apr 30, 2020 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced its commitment to support the identification of antiviral therapies to...

ERS Genomics and Axxam announce CRISPR-Cas9 license agreement to enhance discovery services

Axxam and ERS Genomics announce CRISPR-Cas9 license agreement to enhance discovery services Apr 2, 2020 Milan (Italy) and Dublin (Ireland) - 2 April 2020 - ERS Genomics Limited (“ERS Genomics”), which was formed to provide broad access to the foundational CRISPR-Cas9...

Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms

Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms Jan 14, 2020 Milan (Italy) and Leiden (Netherlands) - 14 January 2019 - Axxam, the leading drug discovery company with expertise in early phase discovery biology, and ZoBio,...

Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH

Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH Jan 10, 2019 Milan (Italy)/Constance (Germany) - Axxam announces the appointment of Dr. Thilo Enderle as Chief Executive Officer of Hit Discovery Constance (HDC), a joint...

Axxam SpA expands to Denmark; opens office in Copenhagen

Axxam SpA expands to Denmark; opens office in Copenhagen Sep 27, 2018 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds,...

Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain

Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Milan (Italy), 20 September 2018 Axxam is proud to announce its participation to a consortium of international partners, held by the Danish...

Axxam SpA is a member of the RESOLUTE consortium

Axxam SpA is a member of the RESOLUTE consortium Milan, 4th July 2018. Axxam is proud to announce its participation to the RESOLUTE (Research empowerment on solute carriers) consortium, a public-private research partnership supported by the Innovative Medicines...

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio

Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio May 14th, 2018 - Milan (Italy) - Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to...

Subscribe to Our Newsletter 

Follow us on